capecitabine + icrucumab

Capecitabine + icrucumab is a combination therapy consisting of capecitabine, an orally administered prodrug of 5-fluorouracil (5-FU), and icrucumab (IMC-18F1), a recombinant human IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor 1 (VEGFR-1). Capecitabine is widely used in the treatment of advanced breast cancer and other malignancies due to its antimetabolite activity that interferes with DNA synthesis. Icrucumab binds specifically to VEGFR-1 with high affinity, blocking the binding of activating VEGF ligands and thereby inhibiting VEGFR-1–mediated proliferation and migration of endothelial cells. This dual approach aims to suppress tumor growth by both direct cytotoxicity (capecitabine) and antiangiogenic effects (icrucumab). The combination has been evaluated in phase II clinical trials for patients with unresectable locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes[2][3][6].

Other names

capecitabineicrucumab